Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human immunodeficiency virus-associated lymphoma.

Samir Parekh1, Howard Ratech, Joseph A Sparano

  • 1Albert Einstein College of Medicine, USA.

Clinical Advances in Hematology & Oncology : H&O
|October 15, 2005
PubMed
Summary

Human immunodeficiency virus (HIV) infection increases the risk of lymphomas, including systemic non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026
Same author

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Blood neoplasia·2026
Same author

"Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality.

Cancer·2026
Same author

Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.

medRxiv : the preprint server for health sciences·2026
Same author

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.

JCO oncology advances·2026
Same author

Timing and Pattern of Extraosseous Dissemination Are Key Determinants of Survival in Multiple Myeloma.

American journal of hematology·2026

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Background:

  • HIV infection is linked to a higher incidence of lymphomas, including systemic non-Hodgkin's lymphoma, Hodgkin's disease, and primary central nervous system lymphoma (PCNSL).
  • Systemic lymphomas in HIV-infected individuals often present with extranodal involvement and intermediate-to-high grade histology.
  • Primary central nervous system lymphoma (PCNSL) in HIV patients is associated with advanced immunodeficiency and a poor prognosis.

Purpose of the Study:

  • To review the clinical presentation, treatment, and prognosis of HIV-associated lymphomas.
  • To highlight the challenges in managing these malignancies in the context of compromised immunity.

Main Methods:

  • Review of existing literature on HIV-associated lymphomas.
  • Analysis of treatment outcomes and prognostic factors.

Main Results:

  • A significant proportion of HIV-associated systemic lymphomas are extranodal and intermediate-to-high grade.
  • Treatment with standard cytotoxic regimens yields cure rates of 33%-50% for systemic lymphomas.
  • HIV-associated Hodgkin's disease often has extranodal involvement and mixed cellularity histology, indicating a poorer prognosis.

Conclusions:

  • Management requires integrated treatment of HIV infection, infection prophylaxis, and lymphoma therapy.
  • Colony-stimulating factors are frequently used to mitigate the risk of febrile neutropenia.
  • While some treatments show success, the prognosis for HIV-associated lymphomas, particularly PCNSL, remains challenging.

Related Experiment Videos